-
Je něco špatně v tomto záznamu ?
Tumour devascularisation as a potential immunotherapeutic strategy
T. Buchler, P. Vasek, R. Spisek, P. Skrobanek, V. Horejsi,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
Perzistentní odkaz
https://www.medvik.cz/link/bmc19001438
- Publikační typ
- časopisecké články MeSH
Complete tumour devascularisation (CTD) is a surgical technique which entails the complete disruption by ligation or cutting of afferent and efferent tumour vasculature which remains in situ. In some animal models, CTD induces immune responses that lead to regression of distant metastases and protective immunity.
EUC Premium s r o Brno Czech Republic
Institute of Molecular Genetics of the Czech Academy of Sciences Prague Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19001438
- 003
- CZ-PrNML
- 005
- 20190115111415.0
- 007
- ta
- 008
- 190107s2019 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1080/2162402X.2018.1526614 $2 doi
- 035 __
- $a (PubMed)30546967
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Buchler, Tomas $u Department of Oncology, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic.
- 245 10
- $a Tumour devascularisation as a potential immunotherapeutic strategy / $c T. Buchler, P. Vasek, R. Spisek, P. Skrobanek, V. Horejsi,
- 520 9_
- $a Complete tumour devascularisation (CTD) is a surgical technique which entails the complete disruption by ligation or cutting of afferent and efferent tumour vasculature which remains in situ. In some animal models, CTD induces immune responses that lead to regression of distant metastases and protective immunity.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Vasek, Pavel $u EUC Premium s.r.o., Brno, Czech Republic.
- 700 1_
- $a Spisek, Radek $u Department of Immunology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.
- 700 1_
- $a Skrobanek, Pavel $u Department of Oncology, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic.
- 700 1_
- $a Horejsi, Vaclav $u Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic.
- 773 0_
- $w MED00190079 $t Oncoimmunology $x 2162-4011 $g Roč. 8, č. 1 (2019), s. e1526614
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30546967 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190107 $b ABA008
- 991 __
- $a 20190115111625 $b ABA008
- 999 __
- $a ind $b bmc $g 1365270 $s 1039561
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 8 $c 1 $d e1526614 $e 20181011 $i 2162-4011 $m Oncoimmunology $n Oncoimmunology $x MED00190079
- LZP __
- $a Pubmed-20190107
